References: UK Statutory Instrument 2004/1031 (as amended) Medicines for Human Use (Clinical Trials) Regulations
Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Starting with low doses and increasing gradually helps reduce the likelihood of this problem
Maximum benefits typically appear after several weeks of consistent use
It is legality, pharmacy legitimacy, formulation, dosing, oversight, side effects, and whether an FDA-approved option is safer or more appropriate
Primary structure properties of fusion proteins Physical and chemical characteristics of engineered fusion proteins, including all molecular weight, molecular formula, theoretical isoelectric point (pI), the total number of positive and negatively charged residues in the sequence, extinction coefficient (E), instability index (II), aliphatic index (AI), and grand average hydropathy (GRAVY), were attained using the Expasy ProtParam server 63